First safety results of an international phase II study evaluating oral vinorelbine as a single agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial).
2014 ◽
Vol 32
(15_suppl)
◽
pp. 1048-1048